SCHEMBL23975979

SCHEMBL23975979

Fc1cccc(-n2cnnc2CCl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
KEAP1 Q14145 1/20 0.41
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
MAPK1 P28482 1/20 0.40
NOTUM Q6P988 1/20 0.39
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
LGALS3 P17931 1/20 0.35
OPRD1 P41143 2/20 0.35
RXRA P19793 3/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2B Q13224 3/20 0.35
OPRM1 P35372 1/20 0.34
MAPK14 Q16539 1/20 0.34
POLB P06746 1/20 0.34
THRB P10828 1/20 0.34
C1S P09871 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225176 1.00 KMT2A (0.43) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL23975978 0.84 NOTUM (0.49) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL23975974 0.81 KMT2A (0.40) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL23975970 0.81 MAPK1 (0.43) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL10719067 0.76 KMT2A (0.46) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL22863629 0.70 NPC1 (0.42) KMT2A
SCHEMBL30431316 0.69 NOTUM (0.49) MAPK1NOTUMMGLLLGALS3OPRD1
SCHEMBL29678030 0.69 OPRD1 (0.53) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL30232873 0.67 OPRD1 (0.42) KMT2AKEAP1PI4KAPI4K2BPI4K2A
SCHEMBL25100216 0.67 OPRD1 (0.42) KMT2AKEAP1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 KMT2A 4375/4885KEAP1 135/4885PI4KA 4254/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI KMT2A 4677/4885KEAP1 45/4885PI4KA 2340/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI KMT2A 4677/4885KEAP1 45/4885PI4KA 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.